Drug Eluting Stent (DES) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Drug Eluting Stent (DES) Market

The global healthcare industry has witnessed remarkable advancements in cardiovascular treatments, and drug-eluting stents (DES) have emerged as a critical innovation in interventional cardiology. These stents, coated with medication to prevent artery blockage, have significantly reduced the need for repeat procedures and improved patient outcomes. According to Fortune Business Insights, the global DES market was valued at USD 5.71 billion in 2018 and is projected to reach USD 9.58 billion by 2026, growing at a compound annual growth rate (CAGR) of 6.6% during the forecast period.

Understanding Drug-Eluting Stents

A drug-eluting stent is a small, expandable mesh tube inserted into a narrowed artery to restore blood flow. Unlike bare-metal stents, DES releases medication over time to prevent restenosis (re-narrowing of the artery), reducing the risk of future cardiac events. These stents have revolutionized the treatment of coronary artery disease (CAD), offering a minimally invasive alternative to traditional bypass surgery.

Market Growth Drivers

Several factors contribute to the expansion of the DES market:

1. Rising Prevalence of Cardiovascular Diseases – The increasing incidence of heart diseases due to sedentary lifestyles, unhealthy diets, and rising stress levels has boosted the demand for DES. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally.

2. Aging Population – With a growing elderly population, the need for cardiac interventions has surged. Older adults are at a higher risk of developing atherosclerosis, necessitating the use of DES.

3. Technological Advancements – Innovations in stent design, such as bioresorbable and polymer-free drug-eluting stents, have improved patient outcomes by reducing complications and enhancing long-term efficacy.

4. Increased Awareness and Accessibility – Rising awareness among patients and healthcare providers about the benefits of DES, along with improved healthcare infrastructure in developing economies, has expanded the market reach.

Regional Insights

The DES market exhibits strong growth across various regions:

North America – The region holds a dominant share due to advanced healthcare systems, high adoption rates of new technologies, and a significant number of cardiovascular cases. The presence of key players like Abbott Laboratories and Boston Scientific further strengthens the market.

Europe – The European market is expanding due to government initiatives for improved cardiac care and increasing awareness of minimally invasive procedures.

Asia-Pacific – Countries like China, India, and Japan are witnessing rapid growth, driven by rising healthcare expenditures, an aging population, and increasing cases of coronary artery disease. The Indian DES market, for instance, generated USD 279.2 million in 2023 and is expected to reach USD 539.8 million by 2030, reflecting a CAGR of 9.9%.

Latin America and the Middle East & Africa – These regions are gradually adopting advanced cardiovascular treatments, though market penetration remains lower compared to developed economies.

Key Players in the Market

The DES market is highly competitive, with several leading companies investing in research and development to enhance product efficacy. Notable players include:

Abbott Laboratories

Boston Scientific Corporation

Medtronic

Terumo Corporation

Biosensors International

Cook Medical

B. Braun

Biotronik

Lepu Medical Technology

These companies focus on developing next-generation stents with improved drug coatings and biodegradable materials to enhance safety and effectiveness.

Challenges and Future Outlook

Despite the promising growth, the DES market faces challenges such as high costs, regulatory hurdles, and concerns over long-term complications. However, continuous research in stent technology, such as fully dissolvable stents and innovative drug coatings, is expected to address these concerns.

Looking ahead, the market is poised for robust growth, driven by increasing investments in healthcare infrastructure, rising demand for minimally invasive procedures, and ongoing technological advancements. As new players enter the market and existing companies refine their products, drug-eluting stents will continue to be a cornerstone in the treatment of cardiovascular diseases, offering patients safer and more effective solutions.

ATTRIBUTE DETAILS

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Historical Period 2015-2017

Unit Value (USD billion)

Segmentation By Type

Coronary Stenting

Peripheral Stenting

By Scaffold

Cobalt-Chromium

Platinum-Chromium

Nitinol

Others

By Drug

Sirolimus

Paclitaxel

Zotarolimus

Everolimus

Others

By End User

Hospitals

Specialty Clinics

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.